F.D.A. Panel Votes to Restrict Avandia - Prescriptions Blog - NYTimes.com

F.D.A. Panel Votes to Restrict Avandia - Prescriptions Blog - NYTimes.com: "A majority of the advisory panel of the Food and Drug Administration voted today to restrict the sales of Avandia, a controversial diabetes drug, because of its potential risk for causing heart attacks. The 33-member advisory committee was deeply divided. Twelve voted to remove Avandia from the market altogether; 10 for continued sale but with new label revisions and possible restrictions; 7 to add more warnings and 3 for no change at all.
But the votes can also be viewed as a decision by a majority, 21, to continue allowing sales of Avandia, with more restrictions. A final decision will be made by the F.D.A. at a later date."

Debate rages on the net about the value of today's ODAC. It will be interesting to see how the market place reacts to today's news. All this adverse publicity has already damaged Avandia, but after all this if the drug does stay on the market will it get any use at all.
Post a Comment

Popular posts from this blog

Learning from your mistakes

Philadelphia Airport